Search the Newsreel

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 5.7% year on year to $12.97 billion. The company's full-year revenue guidance of …

Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bristol Myers Squibb (BMY) reported $12.97 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.7%. EPS of $2.04 for the same period compares to $1.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of …

Bristol Myers Squibb erhöht die Prognose für 2026 nach besser als erwarteten Ergebnissen im zweiten Quartal.

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares up

Investing.com -- Bristol-Myers Squibb shares rose more than 1% in premarket trading Thursday after the drugmaker posted second-quarter results well ahead of expectations and raised its full-year guidance. The company reported earnings per share of $2.04, beating the analyst estimate of $1.61. Revenue came …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Bristol-Myers Squibb superaron 0.43$ las previsiones de BPA en el segundo trimestre del año

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Revenue: Total revenue increased 5% year-over-year to approximately $13 billion. Growth Portfolio Revenue: Rose 14% to $7.6 billion, now representing nearly 60% of total revenue. Eliquis Revenue: Approximately $4.5 billion, up 21%, driven by strong demand and market …

Bristol Myers Lifts Outlook as Profit, Revenue Rise

Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …

How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Bristol-Myers Squibb Company will release earnings for its second quarter before the opening bell on Thursday, July 30. Analysts expect the company to report quarterly earnings of …

Bristow Group Inc (VTOL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bristow Group Inc (VTOL), noting its current valuation score and ranking within the Passenger Transportation Services industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet …

Edgestream Partners L.P. Buys Shares of 154,427 Bristol Myers Squibb Company $BMY

Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …

Bristow Group Inc Today's Market Trends | VTOL Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

Bristow Group Inc. (VTOL) is a provider of vertical flight solutions, primarily offering aviation services to offshore energy companies and government entities. The company's fundamentals are strong with high growth potential, and its stock is considered fairly valued. Analysts have rated VTOL as "Buy" …

Bristol-Myers Squibb (NYSE: BMY) grows Q2 revenue to $12.97B

Informe de resultados: Bristol Myers supera las estimaciones del segundo trimestre de 2026

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

Bristol Myers Squibb hebt Prognose an nach Wachstumsschub - Aktie steigt vorbörslich

¿Han cambiado la presentación conjunta de la solicitud de Opdivo y la expansión de la I+D impulsada por la IA el enfoque de inversión de Bristol-Myers Squibb (BMY)?

Bristow Group Inc (VTOL) Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Bristow Group Inc (VTOL) by TradingKey. It highlights that the company's fundamentals are healthy, growth potential is high, and valuation is considered fairly valued. Analyst ratings are generally positive, with a "Buy" consensus and a target …

Enterprise value to EBITDA forward of Bristow Group, Inc. – BOATS:VTOL

This article provides the enterprise value to EBITDA forward for Bristow Group, Inc. (VTOL). It appears to be a financial data snippet from a platform like TradingView, with no additional textual analysis or details provided.

Bristol Myers Squibb (BMY) Stock May Be 48% Below Fair Value On Fresh AI Drug Discovery News

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bristol-Myers Squibb stock has delivered a 42.2% return over the past year, while the current checks suggest the shares are not a straightforward bargain or …

Bank Syariah Indonesia Number of Employees 2026 | Employee Count & Headcount Data

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here's what to look for. Bristol-Myers Squibb beat analysts' revenue expectations last quarter, reporting revenues of $11.49 billion, up …

The Manufacturers Life Insurance Company Raises Stock Holdings in Bristol Myers Squibb Company $BMY

The Manufacturers Life Insurance Company increased its holdings in Bristol Myers Squibb (NYSE:BMY) by 15.8% in the first quarter, adding 241,405 shares to reach a total value of approximately $107.1 million. Institutional investors now own 76.41% of BMY, while analyst sentiment remains mixed with …

Opal Capital LLC Buys Shares of 22,664 Bristol Myers Squibb Company $BMY

Opal Capital LLC recently acquired 22,664 shares of Bristol Myers Squibb (NYSE:BMY) in the first quarter, valued at approximately $1,375,000. Other institutional investors have also adjusted their holdings in the biopharmaceutical company, which has seen its stock perform within a 12-month range of $42.52 …

Higher Earnings Forecasts and Opdivo Combo Filing Might Change The Case For Investing In Bristol-Myers Squibb (BMY)

In recent days, Bristol Myers Squibb has been in focus as analysts updated earnings forecasts and a biotech partner sought approval for its first commercial product to be used alongside BMS's cancer drug Opdivo. At the same time, commentators have highlighted Bristol Myers Squibb's …

BMY|Bristol-Myers Squibb Co|Price:63.635|Chg%:+1.075

This article provides a comprehensive overview of Bristol-Myers Squibb Co (BMY) stock, including real-time quotes, key financial figures, performance trends, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The stock is currently rated …

California State Teachers Retirement System Has $201.19 Million Stake in Bristol Myers Squibb Company $BMY

The California State Teachers Retirement System reduced its stake in Bristol Myers Squibb Company (BMY) by 2.3% in the first quarter, now owning 3,317,201 shares valued at $201.19 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts currently rate …

Bristol Myers Squibb Company $BMY Shares Sold by Empowered Funds LLC

Empowered Funds LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 38.0% during the first quarter, selling 210,880 shares and leaving them with 344,513 shares valued at over $20 million. Other institutional investors like Swiss RE Ltd., Darwin Wealth Management LLC, …